Welcome to our dedicated page for Inogen SEC filings (Ticker: INGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inogen SEC filings document a respiratory medical technology business that develops, manufactures, markets, sells, and rents respiratory products for homecare use. Results filings and annual proxy materials cover operating performance, executive compensation, director elections, board committees, equity plans, and stockholder voting matters.
Recent Form 8-K disclosures also record share repurchase authorization, leadership and compensatory arrangements, material governance agreements, and Regulation FD communications. The filing record ties these corporate actions to Inogen’s common stock, board oversight, and product portfolio in portable oxygen, airway clearance, stationary oxygen, and CPAP categories.
Inogen, Inc. develops and rents respiratory products such as portable and stationary oxygen concentrators, airway clearance devices, and CPAP masks. For the three months ended June 30, 2026, revenue was 95,084 (amounts in thousands), up 3.0% from 92,277, driven by 5.5% growth in sales revenue and 14.8% growth in international sales, partly offset by an 11.8% decline in U.S. rental revenue due to fewer patients on service.
Total gross margin improved to 45.5% from 44.8%, as higher sales volumes and lower component and warranty costs lifted sales margins, while rental margins declined on higher logistics costs per patient. Operating expenses were 48,368, yielding a loss from operations of 5,096, compared with 6,129 a year earlier. Net loss for the quarter was 3,850 (basic and diluted EPS $(0.14)), and for the first six months net loss was 12,174 (EPS $(0.45)).
As of June 30, 2026, Inogen held 87,276 in cash and cash equivalents, 18,263 in marketable securities, and 1,303 in restricted cash, with total assets of 285,572 and stockholders’ equity of 174,864. Net cash used in operating activities improved to 3,739 for the first six months, from 12,440 in the prior-year period. Under a $30,000 share repurchase program authorized in February 2026, the company bought back and retired 1,145,150 shares for 7,498, leaving 22,502 available under the authorization.
Inogen, Inc. reported second quarter 2026 results with revenue of $95.1 million, up 3.0% year-over-year, and raised full-year adjusted EBITDA guidance to approximately $4.0 million, representing a 48.1% increase from 2025 adjusted EBITDA of $2.7 million.
International sales were $41.3 million, up 14.8%, while U.S. sales and rentals declined, and total gross margin improved to 45.5% from 44.8% a year earlier. GAAP net loss was $3.9 million compared with $4.2 million, and adjusted EBITDA increased to $2.4 million from $2.1 million. The company generated $2.9 million of operating cash flow in the quarter and ended June 30, 2026 with $106.8 million in cash, cash equivalents, marketable securities, and restricted cash and no debt, after repurchasing 1,145,150 shares for $7.5 million in the first half.
Operationally, Inogen reported publication of its QuOTE assessment tool for Long-Term Oxygen Therapy, launch of the Rove 6 portable oxygen concentrator in Canada, completion of Last Patient Last Visit for the Simeox H SCOPE Study in China, and the appointment of a new Chief Operating Officer.
Reding Andrew P. reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc executive Andrew P. Reding, EVP and COO, received a grant of 130,000 restricted stock units. Each unit represents the right to receive one share of Inogen common stock. One-third of the units will vest one year from September 1, 2026, with the remaining two thirds vesting in equal annual installments on the same date in subsequent years, subject to his continued service.
Inogen Inc executive Andrew P. Reding, who serves as EVP and COO, filed an initial Form 3 to report his status as an insider of the company. The filing lists no stock purchases, sales, option exercises, or other transactions, serving only as a baseline ownership report.
Inogen Inc executive Jennifer M. Yi Boyer, EVP Enterprise Enablement and Chief HR Officer, sold 10,938 shares of common stock in an open-market transaction on July 1, 2026 at a weighted average price of $6.5959 per share under a pre-arranged Rule 10b5-1 trading plan.
After this sale, she directly holds 5,039 shares of Inogen common stock.
INGN - Notice of proposed sale of Common stock. The filing lists a proposed sale under a 10b5-1 plan by Jennifer Yi Boyer reporting 10,770 shares dated 05/29/2026. The excerpt also records Restricted Stock Units dated 03/01/2025 with a quantity shown as 10,938 and identifies Morgan Stanley Smith Barney LLC as the broker.
Inogen, Inc. is creating a new Chief Operating Officer role and has appointed Andy Reding, effective July 6, 2026. He will oversee revenue, operations, and cross-functional execution as the company pursues new products and geographic expansion in respiratory care.
Reding’s employment agreement provides a $500,000 annual base salary, a target bonus equal to 70% of salary, and a $100,000 cash sign-on bonus, partially repayable if he departs under certain conditions within two years. Inogen will also reimburse $2,500 of his legal fees related to the agreement.
As an equity inducement, Reding will receive 130,000 time-based RSUs, vesting in three equal annual installments, granted outside existing equity plans under Nasdaq Listing Rule 5635(c)(4). If he is terminated without cause or resigns for good reason, he may receive salary continuation and subsidized medical benefits for 12 months, or 24 months if this occurs around a change of control, subject to a release of claims and other conditions.
Inogen, Inc. reported results of its annual stockholder meeting and changes to its equity compensation plan. Stockholders approved an Amended and Restated 2023 Equity Incentive Plan that increases the shares of common stock available for awards by an additional 750,000 shares, effective upon approval.
Two Class III directors, Glenn Boehnlein and Mira Sahney, were re-elected, and Deloitte & Touche LLP was ratified as independent auditor for the year ending December 31, 2026. Stockholders approved executive compensation on an advisory basis and the equity plan, while an amendment to declassify the board was not approved. About 20,844,941 of 27,324,616 entitled shares were represented, a turnout of approximately 76.28%.
Sahney Mira Kirti reported acquisition or exercise transactions in this Form 4 filing.
Inogen director Mira Kirti Sahney received an equity grant of 28,081 shares of Common Stock through a restricted stock unit award. The grant date was June 5, 2026.
The award vests on the earlier of the one-year anniversary of the grant or the day prior to the next Annual Meeting of stockholders, subject to her continued service. After this grant, she directly holds 67,805 shares of Inogen stock. This is compensation-related, not an open-market purchase.
Jamali Vafa reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc director Jamali Vafa received a grant of 28,081 shares of common stock as a restricted stock unit award on June 5, 2026, at no cash cost. Following the award, Vafa directly holds 43,081 shares. The restricted stock units vest on the earlier of one year after grant or the day before the next annual stockholder meeting, subject to continued service.